Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas

BACKGROUND: For patients with metastatic pancreatic cancer, FOLFIRINOX (fluorouracil [5-FU], leucovorin [LV], irinotecan [IRI], and oxaliplatin) has shown improved survival rates compared with gemcitabine but with significant toxicity, particularly in patients with a high tumor burden. Because of re...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Ann Surg Oncol
Autores principales: Blazer, Marlo, Wu, Christina, Goldberg, Richard M., Phillips, Gary, Schmidt, Carl, Muscarella, Peter, Wuthrick, Evan, Williams, Terrence M., Reardon, Joshua, Ellison, E. Christopher, Bloomston, Mark, Bekaii-Saab, Tanios
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4373613/
https://ncbi.nlm.nih.gov/pubmed/25358667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-014-4225-1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares